Abicipar Pegol has been used in trials studying the treatment of Macular Edema and Macular Degeneration.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Peginterferon alfa-2a | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Peginterferon alfa-2a. |
| Pegfilgrastim | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegfilgrastim. |
| Peginterferon alfa-2b | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Peginterferon alfa-2b. |
| Pegaspargase | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegaspargase. |
| Pegademase | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegademase. |
| Pegvisomant | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegvisomant. |
| Propylene glycol | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Propylene glycol. |
| Heptaethylene glycol | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Heptaethylene glycol. |
| Pegaptanib | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegaptanib. |
| Egaptivon pegol | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Egaptivon pegol. |
| PEG-uricase | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with PEG-uricase. |
| Peginterferon alfacon-1 | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Peginterferon alfacon-1. |
| GlycoPEG-GCSF | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with GlycoPEG-GCSF. |
| Pegnivacogin | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegnivacogin. |
| Pegpleranib | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegpleranib. |
| Pegsunercept | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegsunercept. |
| Polidocanol | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Polidocanol. |
| Peginesatide | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Peginesatide. |
| Certolizumab pegol | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Certolizumab pegol. |
| Methoxy polyethylene glycol-epoetin beta | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Methoxy polyethylene glycol-epoetin beta. |
| Peginterferon beta-1a | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Peginterferon beta-1a. |
| Pegloticase | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegloticase. |
| Polyethylene glycol | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Polyethylene glycol. |
| Antihemophilic factor (recombinant), PEGylated | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Antihemophilic factor (recombinant), PEGylated. |
| Insulin peglispro | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Insulin peglispro. |
| Eptacog alfa pegol (activated) | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Eptacog alfa pegol (activated). |
| Olaptesed Pegol | The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Olaptesed Pegol. |
| Lexaptepid pegol | The therapeutic efficacy of Lexaptepid pegol can be decreased when used in combination with Abicipar Pegol. |
| Cepeginterferon alfa-2B | The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Abicipar Pegol. |
| Pegvaliase | The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Abicipar Pegol. |
| Pegamotecan | The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Abicipar Pegol. |
| Lipegfilgrastim | The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Abicipar Pegol. |
| Nonacog beta pegol | The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Abicipar Pegol. |
| Damoctocog alfa pegol | The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Abicipar Pegol. |
| Elapegademase | The therapeutic efficacy of Elapegademase can be decreased when used in combination with Abicipar Pegol. |
| Rurioctocog alfa pegol | The therapeutic efficacy of Rurioctocog alfa pegol can be decreased when used in combination with Abicipar Pegol. |